Pasar al contenido principal

ANALISIS DE LAS CARACTERISTICAS CLINICAS Y LA PATOGENIA DE LOS ANTICUERPOS CONTRA LA GLYCOPROTEINA DE LA MIELINA OLIGODENDROCITARIA (MOG) EN ADULTOS CON UN PRIMER EVENTO DESMIELINIZANTE

PI20/00800

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Centro realización INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

  • Villacieros-Álvarez, Javier
  • Espejo, Carmen|||0000-0001-9949-5901
  • Arrambide, Georgina|||0000-0002-2657-5510
  • Dinoto, Alessandro|||0000-0002-3249-4792
  • Mulero, Patricia|||0000-0001-8716-8997
  • Rubio-Flores, Laura|||0000-0001-5570-8055
  • Nieto, Pablo
  • Alcalá, Carmen
  • Meca-Lallana, Jose Eustasio|||0000-0001-5050-9890
  • Millan-Pascual, Jorge|||0000-0003-2112-5964
  • Martínez-García, Pedro
  • Bernard-Valnet, Raphael|||0000-0001-7447-344X
  • González-Suárez, Inés|||0000-0002-9897-0771
  • Orviz, Aída
  • Téllez, Raquel
  • Navarro Canto, Laura
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Martínez Yélamos, Sergio|||0000-0001-9889-2040
  • Cuello, Juan Pablo
  • Alonso, Ana
  • Piñar Morales, Raquel|||0000-0003-3490-4932
  • Álvarez Bravo, Gary|||0000-0003-0342-0177
  • Benyahya, Lakhdar
  • Trouillet-Assant, Sophie|||0000-0001-6439-4705
  • Dyon-Tafan, Virginie
  • Froment Tilikete, Caroline|||0000-0002-1452-1398
  • Ruet, Aurélie|||0000-0002-0020-8739
  • Bourre, Bertrand|||0000-0002-2459-2480
  • Deschamps, Romain|||0000-0001-6291-8771
  • Papeix, Caroline|||0000-0003-4074-6125
  • Maillart, Elisabeth|||0000-0001-7699-0328
  • Kerschen, Philippe|||0000-0002-6450-0691
  • Ayrignac, Xavier|||0000-0003-3834-2981
  • Rovira, Alex|||0000-0002-2132-6750
  • Auger, Cristina|||0000-0001-9846-4767
  • Audoin, Bertrand|||0000-0002-9860-7657
  • Montalban, Xavier|||0000-0002-0098-9918
  • Tintoré, Mar|||0000-0001-9999-5359
  • Mariotto, Sara|||0000-0002-7806-3103
  • Cobo-Calvo, Álvaro|||0000-0002-2574-0721
  • Marignier, Romain|||0000-0002-5967-2800
To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. This retrospective multicentric cohort study included patients aged 16 years and older meeting MOGAD 2023 criteria, with serum samples collected at baseline (≤3 months from disease onset) and follow-up (≥6 months from the baseline), and age-matched and time to sampling-matched patients with multiple sclerosis (MS). Eleven cytokines were assessed using the ELLA system. Data comparisons and statistical analyses between cytokine levels and clinical outcomes were performed. Eighty-eight patients with MOGAD and 32 patients with MS were included. Patients with MOGAD showed higher IL6 (p = 0.036), IL8 (p = 0.012), and IL18 (p = 0.026) baseline levels compared with those with MS, in non-optic neuritis (ON) presentations. BAFF values increased over time, especially in patients with MOGAD treated with anti-CD20 (p = 0.002). Baseline BAFF, CXCL10, IL10, and IL8 levels correlated with disease severity at MOGAD onset (all p < 0.05). Finally, higher baseline BAFF levels predicted lower risk of relapses (hazard ratio 0.41 [0.19; 0.89], p = 0.024). This study suggests a proinflammatory Th17-dominant profile in non-ON MOGAD patients, with a novel finding of a potential protective role of BAFF on relapses. These results shed new light on the pathogenesis of MOGAD, potentially guiding therapeutic decisions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis

  • Villacieros-Álvarez, Javier
  • Espejo, Carmen|||0000-0001-9949-5901
  • Arrambide, Georgina|||0000-0002-2657-5510
  • Castillo Juárez, Mireia|||0000-0001-8979-3219
  • Carbonell-Mirabent, Pere|||0000-0003-1349-9261
  • Rodriguez, Marta
  • Bollo, Luca|||0000-0002-3673-2030
  • Castilló, Joaquín|||0000-0002-8951-6315
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Galan, Ingrid|||0000-0001-5774-4260
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Mongay-Ochoa, Neus|||0000-0002-0338-4797
  • Nos, Carlos|||0000-0002-3830-4910
  • Río, Jordi|||0000-0003-4546-7627
  • Rodríguez Acevedo, Breogán|||0000-0002-0314-753X
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Tur, Carmen|||0000-0003-1849-3184
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Vilaseca, Andreu|||0000-0001-8147-8505
  • Zabalza, Ana|||0000-0003-3860-5251
  • Auger, Cristina|||0000-0001-9846-4767
  • Rovira, Alex|||0000-0002-2132-6750
  • Montalban, Xavier|||0000-0002-0098-9918
  • Tintoré, Mar|||0000-0001-9999-5359
  • Cobo-Calvo, Álvaro|||0000-0002-2574-0721
Objective: Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) distinguish multiple sclerosis (MS) from MOG-associated disease in most cases. However, studies analyzing MOG-Ab at the time of a first demyelinating event suggestive of MS in adults are lacking. We aimed to (1) evaluate the prevalence of MOG-Ab in a first demyelinating event suggestive of MS and (2) compare clinical and paraclinical features between seropositive (MOG-Ab+) and seronegative (MOG-Ab-) patients. Methods: Six hundred thirty adult patients with available serum samples obtained within 6 months from the first event were included. MOG-Ab were analyzed using a live cell-based assay. Statistical analyses included parametric and nonparametric tests, logistic regression, and survival models. Results: MOG-Ab were positive in 17 of 630 (2.7%). Fourteen out of 17 (82.4%) MOG-Ab+ patients presented with optic neuritis (ON) compared to 227of 613 (37.0%) MOG-Ab- patients (p = 0.009). Cerebrospinal fluid-restricted oligoclonal bands (CSF-OBs) were found in 2 of 16 (12.5%) MOG-Ab+ versus 371 of 601 (61.7%) MOG-Ab- subjects (p < 0.001). Baseline brain magnetic resonance imaging (MRI) was normal in 9 of 17 (52.9%) MOG-Ab+ versus 153 of 585 (26.2%) MOG-Ab- patients (p = 0.029). Absence of CSF-OBs and ON at onset were independently associated with MOG-Ab positivity (odds ratio [OR] = 9.03, 95% confidence interval [CI] = 2.04-53.6, p = 0.009; and OR = 4.17, 95% CI = 1.15-19.8, p = 0.042, respectively). Of MOG-Ab+ patients, 22.9% (95% CI = 0.0-42.7) compared to 67.6% (95% CI = 63.3-71.3) of MOG-Ab- patients fulfilled McDonald 2017 criteria at 5 years (log-rank p = 0.003). Interpretation: MOG-Ab are infrequent in adults with a first demyelinating event suggestive of MS. However, based on our results, we suggest to determine these antibodies in those patients with ON and absence of CSF-OBs, as long as the brain MRI is not suggestive of MS. ANN NEUROL 2024;95:116-128.